Spectrum Pharmaceuticals, Inc. provided sales guidance for the quarter ended December 31, 2022. Preliminary net sales for the quarter ended December 31, 2022 is expected to be approximately $10 million.
Spectrum Pharmaceuticals, Inc.
Equities
SPPI
US84763A1088
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+49.41% | 57.87B | |
+41.65% | 40.25B | |
-6.72% | 39.94B | |
-5.96% | 28.54B | |
+12.99% | 26.4B | |
-19.82% | 19.33B | |
+32.35% | 12.4B | |
-0.08% | 12.23B | |
+25.18% | 12.2B |